Monopar Therapeutics Inc (MNPR) Price & Analysis

Compare

569 Followers

MNPR Stock Chart & Stats

$55.21

-$0.61(-2.42%)

At close: Jan 08 4:00 PM EST

$55.21

-$0.61(-2.42%)

Day’s Range― - ―

52-Week Range$26.06 - $105.00

Previous CloseN/A

Volume23.12K

Average Volume (3M)205.77K

Market Cap

$368.95M

Enterprise Value$241.37M

Total Cash (Recent Filing)$143.68M

Total Debt (Recent Filing)$102.24K

Price to Earnings (P/E)―

Beta1.71

Next Earnings

May 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding6,682,584

10 Day Avg. Volume232,440

30 Day Avg. Volume205,770

Financial Highlights & Ratios

PEG Ratio-0.12

Price to Book (P/B)4.57

Price to Sales (P/S)0.00

P/FCF Ratio-39.31

Enterprise Value/Market Cap0.65

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-12.05

Forecast

1Y Price Target

$112.71

Price Target Upside104.15% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-3.23

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy And SafetyLate-stage pivotal results showing meaningful copper mobilization, sustained neurological improvement, and a favorable safety profile position ALXN1840 as a differentiated once-daily therapy that could gain clinician support.

Patient Advocacy And AdherenceStrong patient and caregiver testimony emphasizing once-daily dosing, improved tolerability, and reports of restored function suggests material commercial demand driven by better adherence and quality-of-life benefits.

Regulatory PathwayFDA movement toward accepting a single well-controlled pivotal study as the default raises the chance that existing trial data will be considered sufficient, improving the likelihood of an approval pathway for ALXN1840 according to analysts.

Bears Say

Market Adoption And ReimbursementPhysician preference for lower-cost established therapies and potential reimbursement pressures may limit ALXN1840 use to more severe cases, constraining broader market penetration.

Mechanism And Long-term Safety ConcernsUncertainty about how the drug eliminates unbound copper and lingering expert doubts about long-term safety create scientific risk that could undermine clinician confidence and uptake.

Program History And Execution RiskA prior termination and controversial development history for the asset introduce reputational and execution risk that could increase the chance of setbacks during development or commercialization.

Monopar Therapeutics Inc News

Monopar Therapeutics appoints Susan Rodriguez as CCSO

Monopar Therapeutics (MNPR) announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In...

21d ago

MNPR

MNPR Upcoming Earnings Report: What to Expect?

Monopar Therapeutics Inc (MNPR) is scheduled to report 4th quarter earnings on 03/19/2026. Regarding Q4 estimates, Wall Street...

7d ago

MNPR

Monopar Appoints Chief Commercial and Strategy Officer Rodriguez

Monopar Therapeutics Inc ( ($MNPR) ) has shared an update. On March 2, 2026, Monopar Therapeutics Inc. announced...

21d ago

MNPR

MNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease

BTIG analyst Jeet Mukherjee maintained a Buy rating on Monopar Therapeutics Inc yesterday and set a price target...

2M ago

MNPR

3 Best Stocks to Buy Today, 1/30/2026, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

2M ago

ENGN

MNPR

3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

2M ago

CYTK

MNPR

Monopar Therapeutics initiated with an Overweight at Morgan Stanley

Morgan Stanley analyst Maxwell Skor initiated coverage of Monopar Therapeutics (MNPR) with an Overweight rating and $115 price...

2M ago

MNPR

Monopar Therapeutics: ALXN1840’s Differentiated Efficacy, De‑Risked Profile, and Strong Cash Runway Underpin Overweight/Buy Rating

Monopar Therapeutics Inc (MNPR) has received a new Buy rating, initiated by Morgan Stanley analyst, Maxwell Skor. Maxwell...

2M ago

MNPR

Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Monopar Therapeutics Inc, with...

4M ago

MNPR

Monopar downgraded to Outperform from Strong Buy at Raymond James

Raymond James analyst Christopher Raymond downgraded Monopar Therapeutics (MNPR) to Outperform from Strong Buy with a price target...

4M ago

MNPR

Monopar Therapeutics Reports Increased Cash Reserves Amid Losses

Monopar Therapeutics Inc ( ($MNPR) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

MNPR

Monopar Therapeutics reports Q EPS (48c), consensus (40c)

Cash, cash equivalents and investments as of September 30, 2025, were $143.7 million. Monopar expects that its current...

4M ago

MNPR

Promising Potential of Monopar Therapeutics: Buy Rating Backed by ALXN1840’s Efficacy and Safety Data

Monopar Therapeutics Inc, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jeet Mukherjee...

4M ago

MNPR

Coinbase upgraded, Six Flags downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

4M ago

FUN

MNPR FAQ

What was Monopar Therapeutics Inc’s price range in the past 12 months?

Monopar Therapeutics Inc lowest stock price was $26.05 and its highest was $105.00 in the past 12 months.

What is Monopar Therapeutics Inc’s market cap?

Monopar Therapeutics Inc’s market cap is $368.95M.

When is Monopar Therapeutics Inc’s upcoming earnings report date?

Monopar Therapeutics Inc’s upcoming earnings report date is May 07, 2026 which is in 45 days.

How were Monopar Therapeutics Inc’s earnings last quarter?

Currently, no data Available

Is Monopar Therapeutics Inc overvalued?

According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Monopar Therapeutics Inc pay dividends?

Monopar Therapeutics Inc does not currently pay dividends.

What is Monopar Therapeutics Inc’s EPS estimate?

Monopar Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Monopar Therapeutics Inc have?

Monopar Therapeutics Inc has 6,682,584 shares outstanding.

What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Monopar Therapeutics Inc?

Currently, no hedge funds are holding shares in MNPR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Monopar Therapeutics Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-25.72%

Trailing 12-Months

Asset Growth

2275.71%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Monopar Therapeutics Inc

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Monopar Therapeutics Inc (MNPR) Earnings & Revenues

Historic Earnings Reports

MNPR Stock 12 Month Forecast

Average Price Target

$112.71

▲(104.15% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","76":"$76","131":"$131","48.5":"$48.5","103.5":"$103.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$130.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$112.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$101.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,48.5,76,103.5,131],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.48,70.44307692307693,75.40615384615384,80.36923076923077,85.3323076923077,90.29538461538462,95.25846153846155,100.22153846153846,105.18461538461538,110.14769230769231,115.11076923076922,120.07384615384615,125.03692307692307,{"y":130,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.48,69.11307692307693,72.74615384615385,76.37923076923077,80.0123076923077,83.64538461538461,87.27846153846154,90.91153846153847,94.54461538461538,98.1776923076923,101.81076923076922,105.44384615384615,109.07692307692307,{"y":112.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.48,68.21230769230769,70.94461538461539,73.67692307692307,76.40923076923077,79.14153846153846,81.87384615384616,84.60615384615384,87.33846153846154,90.07076923076923,92.80307692307693,95.53538461538461,98.2676923076923,{"y":101,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.93,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.06,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.48,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >